Effects of Occlusion Training on Hockey Players

August 31, 2023 updated by: Riphah International University

Effects of Occlusion Training on Speed and Physical Performance in Hockey Players

Occlusion training is simply a way of restricting blood flow in the veins of a working muscle in hopes to kick-start some larger gains in muscle size and strength. Occlusion training performed during hockey training on speed and physical performance of hockey players. This training also known as blood flow restriction training, can be defined as the training of muscles while limiting blood flow to the muscles and typically done by performing high intensity, low weight, lifts while using some form of tourniquet or band to limit blood supply to limb being trained.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be a randomized controlled trial and total sample size of both groups will be 18 and calculated through non-probability sampling technique and the players will allocate into two groups, control group and experimental group, per group sample size is 9. Each will perform the session for occlusion training. Before and after training sessions players completed a series of test to assess their speed and physical performance. Occlusion training will help us providing unique beneficial training mode for promoting muscle hypertrophy. In control group players will perform general exercises session and in experimental sessions players will perform with occlusion training which is blood flow resistance training (BFR training shoulder, leg extension, bicep curls, kaatsu) 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time and pull-ups performed at 70% of 1-repetition maximum. This training will also improve and increase muscular strength in players.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
18

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male
  • Athletes with age group of 19-30 years of age.
  • All players who had a minimum of two years of resistance training experience

Exclusion Criteria:

  • Systemic issues with orthopedic issue, fractures, neuromuscular issue, cardiac issues.
  • Players having history of prior surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Occlusion Training
Other: Occlusion Training
In experimental sessions players will perform with occlusion training which is blood flow resistance training, 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time.This training will also improve and increase muscular strength as well as speed and physical performance in players.
Active Comparator: General exercises without occlusion
Other: General Exercises without occlusion training
General Exercises as bench press, squats , maximum sprint, leg power without occlusion training

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
SQUATS
Time Frame: 4 weeks
The squats test is a simple, yet effective way to monitor leg strength on a regular basis. To conduct this test a chair or box that makes the players knees bend at right angles when they are sitting. The players warm up for 10 minutes. Players stands in front of a chair, facing away from it, with their feet shoulder-width apart. The players squats down, lightly touching the chair with their backside before standing back up and repeats this sequence of movements until they are unable to continue.The assistant counts and records the number of completed squats.
4 weeks
BENCH PRESS
Time Frame: 4 WEEKS
The objective of the bench press test is to evaluate an player's upper body strength. For bench press test for hockey players requirements are Barbell and weights, Weighing Scales and Bench. This test requires the athlete to complete as many bench presses as possible with no rest. The assistant weighs and records the athlete's weight. The players warm up for ten minutes .The assistant loads the barbell with a weight close to the players one repetition maximum load. The player conducts bench presses until they are unable to continue. The assistant acts as a spotter for the athlete and counts the number of successful bench presses. If the number of bench presses exceeds ten, then the athlete rests for ten minutes, the assistant increases the barbell weight, and the player repeats the test.
4 WEEKS
MAXIMUM TIME SPRINT
Time Frame: 4 WEEKS
Sprints are used to primarily test an players acceleration. Max speed is directly linked to initial acceleration so testing sprint times at smaller initial intervals give a picture of whether training is improving acceleration and therefore max speed. This test involves a 40m sprint with 5m acceleration/deceleration spaces on either end of the test track. Timing lights are placed at 5m and 35m respectively. The players must complete 6 trials, with each trial beginning at 30-second intervals (0s, 30s, 60s, etc). Electronic timing gates are to be set up at the 0, 10, 30 and 40m marks Players start in a two-point standing stance, with the front foot in between the set of cones placed at the start line. 3 attempts are allowed. Players may remove themselves from testing once they feel they have given a maximal attempt. Data required: time for 10m, 30m, and 40m recorded to the nearest 0.01sec.
4 WEEKS
LEG POWER
Time Frame: 4 WEEKS
The Power Index is a simple measure that is determined by calculating the square root of the athlete's body weight (in pounds) and multiplying it by the square root of their vertical jump (in inches). Drop Jump a test of leg strength and power which requires the athlete to drop off a box and immediately jump as high as they can. Standing Long (Broad) Jump Test: jump off two legs for maximal distance, a measure of leg power. The Vertical Jump Test can be performed to measure leg power.
4 WEEKS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Amna Shahid, t-DPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 25, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 15, 2023

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 22, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 18, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 1, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 1, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 31, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/23/0403

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings